araag2/HINT huggingface dataset:
Clinical trial NCT02235987 (phase 2, status: completed)
Conditions: acromegaly
ICD codes: E22.0
Drugs: octreotide, dg3173
SMILES: [H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)O, C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CCCNC(=O)CCCN(CC(N)=O)C(=O)[C@H](CC2=CC=CC=C2)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men, women of non childbearing potential or women of child bearing potential who
             either abstain from sexual intercourse, have a sterile partner or practice a medically
             approved double barrier method of contraception

          -  Diagnosis of acromegaly of pituitary origin

          -  Have age adjusted Insulin like Growth Factor 1 (IGF-1) concentrations ≥1.5 times the
             upper limit of normal range on two consecutive measurements in the 6 months prior to
             the first dosing day (including the measurement to be made at screening [Visit 2])

          -  Have a random hGH level of ≥5 µg/L in the 6 months prior to or at screening (Visit 2)

          -  Have given written informed consent

          -  Ability to comply with the requirements of the protocol of the study

        Exclusion Criteria:

          -  Previous specific treatment for acromegaly in the 6 months prior to screening (Visit
             2), including somatostatin analogues (SSAs), surgery, radiotherapy and pegvisomant

          -  Treatment with dopamine agonists in the 3 months prior to screening (Visit 2)

          -  Uncontrolled hypertension or orthostatic hypotension

          -  Type I diabetes mellitus, poorly-controlled type II diabetes mellitus (glycosylated
             haemoglobin [HbA1c]≥7.5%) and patients requiring insulin treatment

          -  Gallstones or gravel that could cause biliary obstruction

          -  Hyperprolactinaemia

          -  Participation in a clinical study within 60 days prior to screening (Visit 2)

          -  Receipt of blood, blood products or plasma derivatives 60 days prior to screening
             (Visit 2)

          -  Pregnancy or lactation

          -  A history of active alcohol abuse or drug addiction

          -  Positive viral serology screening result for hepatitis B surface antigen, antibodies
             to hepatitis C virus, or human immunodeficiency virus type 1 and 2

          -  Evidence or suspicion of tumour expansion

          -  Clinically significant abnormality in screening ECG

          -  Any clinically significant abnormal laboratory safety test (biochemistry, haematology
             and dipstick urinalysis) in the opinion of the Investigator

          -  Any disease which in the Investigator's opinion would exclude the patient from the
             study
Clinical trial NCT00088140 (phase 2, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: idn-6556, placebo
SMILES: C[C@H](NC(=O)C(=O)NC1=CC=CC=C1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COC1=C(F)C(F)=CC(F)=C1F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic hepatitis C infection

          -  Unsuccessful prior HCV treatment

          -  Liver impairment (either AST or ALT 1.5-10.0 x ULN)

          -  Alpha-fetoprotein <= 50 ng/mL

          -  Adequate hematologic parameters

        Exclusion Criteria:

          -  Decompensated or severe liver disease

          -  Hepatocellular carcinoma

          -  HIV infection

          -  Co-infection with hepatitis B virus (HBV)

          -  Renal impairment

          -  Pancreatitis

          -  Use of illicit or drugs of abuse

          -  History of alcohol abuse

          -  Presence of clinically significant cardiac arrhythmias

          -  If female, pregnant or lactating
Clinical trial NCT00452777 (phase 2, status: completed)
Conditions: diabetic neuropathic pain
ICD codes: E85.1, E85.0, N31.0, N31.1, N31.2, E10.610, E11.610
Drugs: bvt.115959, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  A diagnosis of type 1 or 2 diabetes mellitus and documented painful, symmetrical,
             sensorimotor polyneuropathy for at least 6 months

          -  Either no analgesic medication or on stable analgesic medication for at least 4 weeks

        Exclusion Criteria:

          -  Female patients who are fertile and of child-bearing potential

          -  Clinically significant or unstable hepatic, respiratory, renal, hematologic,
             cardiovascular or peripheral vascular disease

          -  Painful conditions that may confound the evaluation of neuropathic pain
Clinical trial NCT01248975 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: fp/sal 250/50mcg bid, gsk2190915 200mg qd (am), gsk2190915 100mg qd (am), montelukast 10mg qd (pm), placebo tablets (2) (am), placebo capsule (pm)
SMILES: CCOC1=CC=C(C=N1)C1=CC=C(CN2C(CC(C)(C)C(O)=O)=C(SC(C)(C)C)C3=CC(OCC4=CC=C(C)C=N4)=CC=C23)C=C1, CCOC1=CC=C(C=N1)C1=CC=C(CN2C(CC(C)(C)C(O)=O)=C(SC(C)(C)C)C3=CC(OCC4=CC=C(C)C=N4)=CC=C23)C=C1, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age: 18 years of age or older

          -  Non-, former or current smokers with a documented smoking history of ≤ 10 pack years

          -  Asthma diagnosis as defined by the National Institutes of Health

          -  Best FEV1 of 50% to <80% of the predicted normal value

          -  For current and former smokers, a post-albuterol FEV1/FVC ratio of >0.70 at Visit 1/1a
             (between 5:00AM and 12:00 noon)

          -  ≥ 12% and ≥200mL reversibility of FEV1

          -  Must have been using FP/SAL 250/50mcg inhalation powder BID for at least 2 weeks just
             prior to Visit 1.

          -  Must be able to replace their current short-acting beta2-agonists with albuterol
             inhalation aerosol

          -  Must be able and willing to give written informed consent to take part in the study.

          -  Must be able and willing to comply with all aspects of the study including completion
             of daily e-Diary.

        Exclusion criteria:

          -  History of life-threatening asthma

          -  Recent asthma exacerbation

          -  Concurrent respiratory disease

          -  Recent respiratory infection

          -  Liver disease

          -  Other concurrent diseases/abnormalities

          -  Oral candidiasis

          -  Drug allergy

          -  Milk protein allergy

          -  Immunosuppressive Medications

          -  Administration of systemic, oral or depot corticosteroids within 12 weeks of Visit 1

          -  OATP1B1 substrates within 4 weeks of Visit 1

          -  Cytochrome P450 3A4 (CYP 3A4) Inhibitors

          -  Cytochrome P450 3A4 (CYP 3A4) Inducers

          -  Investigational Medications

          -  Compliance: any infirmity, disability, or geographical location which seems likely (in
             the opinion of the Investigator) to impair compliance with any aspect of this study
             protocol

          -  Affiliation with Investigator's Site
Clinical trial NCT00406874 (phase 2, status: terminated)
Conditions: infertility
ICD codes: N46.8, N46.9, N97.9, N97.0, N97.1, N97.2, N97.8
Drugs: omega 3 fats, folic acid
SMILES: NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1
Reason stopped: 
    reports indicating that increased folic acid intake may increase colin cancer
  
Eligibility criteria:

        Inclusion Criteria:

          -  infertile men

          -  age 35 to 55

          -  expressing difficulty timing relations to their partner's ovulation

        Exclusion Criteria:

          -  hypertension, heart disease or other systemic diseases

          -  fatty fish intake more than twice per week

          -  marked semen abnormalities (less than 10 million sperm per ml, less than 20 % A plus B
             motility, more than 1 million WBC per HPF)

          -  use of anticoagulants

          -  must be willing to not take PDE 5 inhibitors during the study

          -  use of other supplements is prohibited during the study
Clinical trial NCT00417690 (phase 2, status: terminated)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: 4-aminosalicylic acid, paser placebo granules
SMILES: NC1=CC(O)=C(C=C1)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    efforts at recruitment have halted as recruitment was poor.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18-65

          -  Crohn's disease involving predominantly the ileum and/or cecum. The diagnosis must
             have been established by radiography, endoscopy and/or biopsy (at least 2 of the 3
             modalities) with at least one confirmatory test having been performed no more than 36
             months before entry. The diagnosis must have been confirmed by at least one
             gastroenterologist.

          -  Harvey Bradshaw Index of at least 7

          -  The onset of the acute flare should have been abrupt, declaring itself over 72 hours,
             and should have started no more than 4 weeks before study entry. Symptoms relating to
             the flare should not have diminished or started to improve prior to entry.

          -  Written informed consent

        Exclusion Criteria:

          -  Concomitant corticosteroids, including budesonide

          -  Corticosteroids within the previous 2 months

          -  Cyclosporine, mycophenolate mofetil or experimental drugs during the last three months

          -  Maintenance infliximab, or infliximab or other biologics in the preceding 3 months

          -  Change in dose during previous 4 weeks in 5-aminosalicylate, probiotic and/or
             antibiotic, or in chronic azathioprine, 6-mercaptopurine, or methotrexate

          -  If currently using azathioprine, 6-mercaptopurine or methotrexate, these must have
             been used steadily for at least 4 months

          -  Current experimental drugs or experimental drugs within the last 3 months

          -  If the severity of the flare has started to decrease spontaneously

          -  Coexisting diagnosis of primary sclerosing cholangitis,

          -  Infectious diarrhea,

          -  Signs of intestinal obstruction or perforation or abscess,

          -  New fistulization as part of the acute flare or increased activity in chronic
             fistula(e) as part of the acute flare,

          -  Increased activity of pre-existing anal or rectal Crohn's disease as part of the flare

          -  Allergy or sensitivity to salicylates

          -  Pregnancy or breast-feeding

          -  Failure of a woman of child-bearing age to agree to use adequate contraception for the
             4 week period of the trial, if sexually active

          -  Severe renal or hepatic disease
Clinical trial NCT00247676 (phase 2, status: completed)
Conditions: liver neoplasms, unresectable hepatocellular carcinoma
ICD codes: D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6, C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: sunitinib (su011248)
SMILES: CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed diagnosis of hepatocellular carcinoma

          -  Patients must present with disease not amenable to curative surgery (i.e. either
             hepatectomy, or liver transplant).

          -  Evidence of measurable disease by radiographic technique

          -  Adequate organ function.

        Exclusion Criteria:

          -  Prior treatment with any systemic treatment for liver cancer

          -  Presence of clinically relevant ascites

          -  Severe hemorrhage <4 weeks of starting study treatment.

          -  Diagnosis of second malignancy within last 3 years

          -  History of or known brain metastases, spinal cord compression, or carcinomatous
             meningitis

          -  Known human immunodeficiency virus (HIV)

          -  Serious acute or chronic illness

          -  Current treatment on another clinical trial

          -  Pregnant or breastfeeding
Clinical trial NCT00215644 (phase 2, status: completed)
Conditions: esophageal cancer, gastric cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: matuzumab, epirubicin, cisplatin, capecitabine
SMILES: CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed gastric adenocarcinoma or adenocarcinoma of the lower third
             of the esophagus

          -  Metastatic disease

          -  Immunohistological evidence of Epidermal Growth Factor Receptor (EGFR) expression from
             archived tissues

          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1

          -  At least 1 measurable lesion (modified World Health Organization criteria)

        Exclusion Criteria:

          -  Previous chemotherapy, unless neo-adjuvant or adjuvant therapy completed greater than
             (>) 12 months prior to study treatment

          -  Radiotherapy or major surgery within 4 weeks prior to treatment

          -  Brain metastases

          -  Peripheral neuropathy or ototoxicity greater than or equal to (>/=) Grade 2 (National
             Cancer Institute Common Terminology Criteria for Adverse Events Version 3 [NCICTC V3])

          -  Abnormal electrocardiogram (ECG)
Clinical trial NCT00689728 (phase 2, status: completed)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have given written informed consent approval

          -  Women must not be at risk to become pregnant during study participation

          -  Diagnosis of Rheumatoid Arthritis

          -  Active Rheumatoid Arthritis

          -  Current, regular use of Methotrexate, at a stable dose

          -  Have been on at least 1 biologic tumor necrosis factor-alpha (TNFα) inhibitor therapy
             and either failed or were intolerant to treatment

          -  Other criteria to be reviewed by study doctor

        Exclusion Criteria:

          -  Use of excluded medications (reviewed by study doctor)

          -  Have medical findings which, in the opinion of the study doctor, put patient at an
             unacceptable risk for participation in the study

          -  Have had recent or ongoing infection which, in the opinion of the study doctor put
             patient at an unacceptable risk for participation

          -  Evidence of tuberculosis

          -  Have systemic inflammatory condition other than rheumatoid arthritis (RA), such as
             juvenile RA, seronegative spondyloarthropathy, Crohn's disease, ulcerative colitis, or
             psoriatic arthritis.

          -  Other criteria to be reviewed by study doctor
Clinical trial NCT00267592 (phase 2, status: completed)
Conditions: glioblastoma multiforme
ICD codes: L51.0, L51.8, L51.9
Drugs: talampanel, temozolomide(tmz) 75mg, adjuvant tmz 200mg
SMILES: C[C@@H]1CC2=CC3=C(OCO3)C=C2C(=NN1C(C)=O)C1=CC=C(N)C=C1, CN1N=NC2=C(N=CN2C1=O)C(N)=O, CN1N=NC2=C(N=CN2C1=O)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must be 18 years of age

          -  Patients must have histologically confirmed supratentorial Grade IV astrocytoma
             (glioblastoma multiforme)

          -  Patients must not have prior radiation therapy, chemotherapy (including Gliadel
             wafer), immunotherapy or therapy with a biologic agent, or hormonal therapy.
             Glucocorticoid therapy is allowed.

          -  Patients must have recovered from the immediate post-operative period and be
             maintained on a stable corticosteroid regimen (on increase for 5 days) prior to the
             start of treatment.

          -  Patients must have a Karnofsky performance of at least 60% or more.

        Exclusion Criteria:

          -  Patients with serious concurrent infection or medical illness.

          -  Patients receiving concurrent chemotherapeutics or investigational agents.
Clinical trial NCT01006265 (phase 2, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: act-128800 dose 1, placebo, act-128800 dose 2, act-128800 dose 3
SMILES: CCC\N=C1/S\C(=C/C2=CC=C(OC[C@H](O)CO)C(Cl)=C2)C(=O)N1C1=CC=CC=C1C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCC\N=C1/S\C(=C/C2=CC=C(OC[C@H](O)CO)C(Cl)=C2)C(=O)N1C1=CC=CC=C1C, CCC\N=C1/S\C(=C/C2=CC=C(OC[C@H](O)CO)C(Cl)=C2)C(=O)N1C1=CC=CC=C1C
Eligibility criteria:

        Inclusion Criteria:

          -  Adult males and females

          -  Diagnosis of RRMS as defined by the revised (2005) McDonald Diagnostic Criteria for
             Multiple Sclerosis (MS).

          -  Signed inform consent prior to initiation of any study-mandated procedure.

        Exclusion Criteria:

          -  A diagnosis of MS categorized as primary progressive or secondary progressive or
             progressive relapsing.

          -  Patients currently treated for an autoimmune disorder other than MS.

          -  Contraindications for MRI.

          -  Ongoing bacterial, viral, or fungal infection.

          -  History or presence of malignancy.

        Additional inclusion and exclusion criteria apply with respect to medical conditions and
        concomitant treatments which could affect patients' risk from participating in the study.
Clinical trial NCT01194453 (phase 2, status: completed)
Conditions: non-small cell lung cancer, efficacy
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: cisplatin, dexamethasone,vitamin b12, folic acid, cisplatin, gemcitabine
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          1. Chemotherapy-naive patients with histologically or cytologically confirmed
             adenocarcinoma and large-cell carcinoma, classified as stage IIIB not amenable to
             curative treatment or stage IV

          2. With at least one unidimensionally measurable lesion according to the Response
             Evaluation Criteria in Solid Tumors;

          3. with an Eastern CooperativeOncology Group performance status of 0 or 1,

          4. At least 18 years of age

          5. adequate bone marrow reserve and organ function including calculated creatinine
             clearance 45 mL/min based on the standard Cockcroft and Gault formula.

          6. Prior radiation therapy was permitted if it was completed at least 4 weeks before
             study treatment

          7. patients had fully recovered from its acute effects.

        Exclusion Criteria:

          1. peripheral neuropathy > National Cancer Institute Common Toxicity Criteria grade 1

          2. progressive brain metastases,

          3. uncontrolled third-space fluid retention before study entry.

          4. Patients unable to interrupt aspirin and other nonsteroidal anti-inflammatory drugs or
             if they were unable or unwilling to take folic acid, vitamin B12, or corticosteroids.
Clinical trial NCT01269346 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: eribulin mesylate
SMILES: [H][C@@]12O[C@@]3([H])CCC4CC(=O)C[C@H]5[C@H](C[C@H]6O[C@H](C[C@@H](C)C6=C)CC[C@@H]6O[C@H](CC6=C)CC[C@@]67C[C@@H](O[C@H]1[C@@H](O6)[C@@]3([H])O4)[C@@H]2O7)O[C@H](C[C@H](O)CN)[C@@H]5OC
Eligibility criteria:

        Key Inclusion criteria:

          -  Age 18 years or older

          -  Histologically or cytologically proven adenocarcinoma of the breast

          -  Subjects who have locally recurrent or metastatic disease with at least one measurable
             lesion

          -  HER2 positive as determined by score of 3 on immunohistochemistry (IHC) staining or
             gene amplification by fluorescence in situ hybridization (FISH).

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0, 1 or 2

          -  At least 12 months since prior neoadjuvant or adjuvant chemotherapy

          -  At least 2 weeks since prior radiotherapy, endocrine therapy, trastuzumab, or
             lapatinib, with complete recovery from the effects of these interventions

          -  Adequate renal function

          -  Adequate bone marrow function

          -  Adequate liver function

          -  Adequate cardiac function

        Key Exclusion criteria:

          -  Prior chemotherapy, biologic therapy, or investigational therapy for locally recurrent
             or metastatic HER2 breast cancer.

          -  Subjects who have had a prior malignancy other than carcinoma in situ of the cervix,
             or nonmelanoma skin cancer

          -  Prior exposure to greater than 360 mg/m2 doxorubicin or liposomal doxorubicin, greater
             than 120 mg/m2 mitoxantrone, greater than 90 mg/m2 idarubicin, or greater than 720
             mg/m2 epirubicin

          -  Inflammatory breast cancer

          -  Prior history of hypertensive crisis or hypertensive encephalopathy

          -  Clinically significant cardiovascular impairment

          -  Subjects with known central nervous system (CNS) disease are not eligible, except for
             those subjects with treated brain metastasis.

          -  Subjects with metastatic disease limited to bone are ineligible unless there is at
             least one lytic lesion with identifiable soft tissue components that can be evaluated
             by computed tomography (CT) or magnetic resonance imaging (MRI)

          -  Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring the
             use of oxygen

          -  History of bleeding diasthesis

          -  Currently pregnant or breast-feeding.

          -  Subjects with preexisting Grade 3 or 4 neuropathy. Any peripheral neuropathy must
             recover to Grade less than or equal to 2 before enrollment